Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108,074,661
-
Total 13F shares
-
70,071,814
-
Share change
-
-902,529
-
Total reported value
-
$479,974,125
-
Put/Call ratio
-
40%
-
Price per share
-
$6.85
-
Number of holders
-
137
-
Value change
-
-$28,113,579
-
Number of buys
-
80
-
Number of sells
-
48
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q3 2023
As of 30 Sep 2023,
Aclaris Therapeutics, Inc. - Common Stock (ACRS) was held by
137 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
70,071,814 shares.
The largest 10 holders included
BVF INC/IL, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., Rock Springs Capital Management LP, Bain Capital Life Sciences Investors, LLC, VANGUARD GROUP INC, CITADEL ADVISORS LLC, Foresite Capital Management IV, LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
137
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.